var data={"title":"Polyethylene glycol 3350: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol 3350: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/160261?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-3350-drug-information\" class=\"drug drug_general\">see &quot;Polyethylene glycol 3350: Drug information&quot;</a> and <a href=\"topic.htm?path=polyethylene-glycol-3350-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol 3350: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295346\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GaviLAX [OTC];</li>\n      <li>GlycoLax [OTC];</li>\n      <li>HealthyLax [OTC];</li>\n      <li>MiraLax [OTC];</li>\n      <li>PEGyLAX</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23536048\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Relaxa;</li>\n      <li>Restoralax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5599448\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Laxative, Osmotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5599457\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=polyethylene-glycol-3350-drug-information\" class=\"drug drug_general\">see &quot;Polyethylene glycol 3350: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bowel preparation:</b> Limited data available: Children &gt;2 years and Adolescents: Oral: 1.5 g/kg/day for 4 days; maximum daily dose: 100 g/<b>day</b> (Pashankar 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation: </b> Limited data available: Infants, Children, and Adolescents: Oral:  0.2 to 0.8 g/kg/day (NASPGHAN [Tabbers] 2014); higher initial dose of 1 g/kg have been suggested ( Loening-Buck 2004; Pashankar 2001); maximum daily dose: 17 g/day. <b>Note:</b>  Dosage should be individualized to achieved desired effect, infants and young children may require higher doses than school aged children (Loening-Buck  2004; Pashankar 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fecal impaction, slow disimpaction:</b> Limited data available: Children and Adolescents: Oral: 1 to 1.5 g/kg daily for 3 to 6  consecutive days (NASPGHAN [Tabbers] 2014; Youssef 2002); maximum daily dose: 100 g/<b>day</b> (Youssef 2002); following disimpaction maintenance dose of 0.4 g/kg daily should be continued for &ge; 2 months (NASPGHAN [Tabbers] 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bowel preparation:</b> Oral: Mix 17 g of powder (~1 heaping tablespoon) in 8 ounces of clear liquid and administer the entire mixture every 10 minutes until 2 liters are consumed (start within 6 hours after administering 20 mg bisacodyl delayed release tablets) (Wexner 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation, occasional:</b> Oral: 17 g of powder (~1 heaping tablespoon) dissolved in 4 to 8 ounces of beverage, once daily; do not use for &gt;1 week unless directed by healthcare provider</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295374\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HealthyLax:  (1 ea, 14 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax:  (1 ea, 10 ea, 12 ea, 24 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (1 ea, 14 ea, 30 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLAX: 17 g/dose (238 g, 510 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlycoLax: 17 g/dose (119 g, 255 g, 527 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax: 17 g/dose (1 ea, 119 g, 238 g, 510 g, 765 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PEGyLAX: 17 g/dose (527 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 17 g/dose (119 g, 238 g, 250 g [DSC], 255 g, 500 g [DSC], 510 g, 527 g, 850 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295348\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5599505\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bowel preparation for colonoscopy: Stir powder in 8 ounces of clear liquid until dissolved and drink. Oral medications should not be administered within 1 hour of start of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Constipation: Stir powder in 4 to 8 ounces of water, juice, soda, coffee or tea until dissolved and administer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295366\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5599449\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of occasional constipation (OTC product: FDA approved in ages &ge;17 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295345\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax may be confused with Mirapex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polyethylene glycol 3350 may be confused with polyethylene glycol electrolyte solution</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MiraLax may be confused with Murelax brand name for oxazepam [Australia]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295363\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, bloating of the stomach, diarrhea, flatulence, nausea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295357\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to polyethylene glycol or any component of the formulation; known or suspected bowel obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if you have renal disease unless advised by a health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Relaxa: Use in children &lt;18 years of age unless advised by a physician</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295358\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Prolonged, frequent, or excessive use may lead to electrolyte imbalance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity:  Do not use if you are hypersensitive to polyethylene glycol. If an allergic reaction develops (eg, rash, swelling, difficulty breathing), discontinue use immediately and seek medical care.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concern:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction: Evaluate patients with symptoms of bowel obstruction, appendicitis, or inflamed bowel (nausea, vomiting, abdominal pain or distension) prior to use; use is contraindicated in patients with known or suspected bowel obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Do not use in renal impairment unless under supervision of a health care professional.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: If severe diarrhea occurs, discontinue use. When used for bowel preparation for colonoscopy (off-label use), oral medications should not be administered within 1 hour of start of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Do not use for longer than 1 to 2 weeks (product specific); 2 to 4 days may be required to produce bowel movement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: When used for self-medication, patients should consult health care provider prior to use if they have nausea, vomiting, or abdominal pain, irritable bowel syndrome, or a sudden change in bowel habits for &gt;2 weeks. Patients should be instructed to discontinue use and consult health care provider if they have severe diarrhea, rectal bleeding, if abdominal pain, bloating, cramping, or nausea gets worse, or if need to use for &gt;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26888850\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The effects of long-term use or large doses of polyethylene glycol in children are unknown. The FDA has received reports of metabolic acidosis (with and without anion gap) and neuropsychiatric events in children taking polyethylene glycol; however, direct causality with the drug has not been established. Neuropsychiatric adverse events reported may include seizures, tremors, tics, headache, anxiety, lethargy, sedation, aggression, rages, obsessive-compulsive behaviors (including repetitive chewing and sucking), paranoia and mood swings. Studies are underway to define the metabolic processes and pathways polyethylene glycol (and any metabolites) in pediatric patients and to determine gastrointestinal absorption properties if any (FDA 2013). As of 2014, the FDA decided no action was necessary based upon available data (FDA 2014). Monitor pediatric patients closely for signs of metabolic acidosis or neuropsychiatric changes. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299899\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222409\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13070&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Polyethylene Glycol 3350 may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295354\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Polyethylene glycol (PEG) has minimal systemic absorption and would be unlikely to cause fetal malformations. However, until additional information is available, use to treat constipation in pregnancy should be avoided unless other preferred methods are inadequate (Mahadevan 2006). Use as a bowel preparation prior to colonoscopy in pregnant women may be considered (Wexner 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5599506\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Stool frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">An osmotic agent, polyethylene glycol 3350 causes water retention in the stool; increases stool frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295370\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: 24 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Minimal (&lt;0.28%; Pelham, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (93%); urine (0.2%) (Pelham, 2008)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Candy D and Belsey J, &quot;Macrogol (Polyethylene Glycol) Laxatives in Children With Functional Constipation and Faecal Impaction: A Systematic Review,&quot; <i>Arch Dis Child</i>, 2009, 94(2):156-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/19019885/pubmed\" target=\"_blank\" id=\"19019885\">19019885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Co-Minh HB, Demoly P, Guillot B, et al, &quot;Anaphylactic Shock After Oral Intake and Contact Urticaria Due to Polyethylene Glycols,&quot; <i>Allergy</i>, 2007, 62(1):92-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/17156356/pubmed\" target=\"_blank\" id=\"17156356\">17156356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Drug safety Oversight Board Meeting, June 18, 2019. Available at  <a href=\"http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm%20\" target=\"_blank\">http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm</a>. Last accessed January 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between october - december 2011. Available at <a href=\"http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm\" target=\"_blank\">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm</a> Last accessed January 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loening-Baucke V, &quot;Prevalence, Symptoms and Outcome of Constipation in Infants and Toddlers,&quot; <i>J Pediatr</i>, 2005, 146(3):359-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/15756220 /pubmed\" target=\"_blank\" id=\"15756220 \">15756220 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loening-Baucke V, Krishna R, and Pashankar DS, &quot;Polyethylene Glycol 3350 Without Electrolytes for the Treatment of Functional Constipation in Infants and Toddlers,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 39(5):536-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/15572895/pubmed\" target=\"_blank\" id=\"15572895\">15572895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U and Kane S, &quot;American Gastroenterological Association Institute Technical Review on the Use of Gastrointestinal Medications in Pregnancy,&quot; <i>Gastroenterology</i>, 2006, 131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/16831611/pubmed\" target=\"_blank\" id=\"16831611\">16831611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michail S, Gendy E, Preud'Homme D, et al, &quot;Polyethylene Glycol for Constipation in Children Younger Than Eighteen Months Old,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 39(2):197-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/15269628/pubmed\" target=\"_blank\" id=\"15269628\">15269628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miralax powder for solution (polyethylene glocol 3350) [prescribing information]. Memphis TN: MSD Consumer Care, Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nurko S, Youssef NN, Sabri M, et al, &quot;PEG3350 in the Treatment of Childhood Constipation: A Multicenter, Double-Blinded, Placebo-Controlled Trial,&quot; <i>J Pediatr</i>, 2008, 153(2):254-61, 261.e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/18534221 /pubmed\" target=\"_blank\" id=\"18534221 \">18534221 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Bishop WP, and Loening-Baucke V, &quot;Long-Term Efficacy of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children With and Without Encopresis,&quot; <i>Clin Pediatr (Phila)</i>, 2003, 42(9):815-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/14686553/pubmed\" target=\"_blank\" id=\"14686553\">14686553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Loening-Baucke V, and Bishop WP, &quot;Safety of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children,&quot; <i>Arch Pediatr Adolesc Med</i>, 2003, 157(7):661-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/12860787/pubmed\" target=\"_blank\" id=\"12860787\">12860787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Uc A, and Bishop WP, &quot;Polyethylene Glycol 3350 Without Electrolytes: A New Safe, Effective, and Palatable Bowel Preparation for Colonoscopy in Children,&quot; <i>J Pediatr</i>, 2004, 144(3):358-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/15001943 /pubmed\" target=\"_blank\" id=\"15001943 \">15001943 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelham RW, Nix LC, Chavira RE, et al, &quot;Clinical Trial: Single- and Multiple-Dose Pharmacokinetics of Polyethylene Glycol (PEG-3350) in Healthy Young and Elderly Subjects,&quot; <i>Aliment Pharmacol Ther</i>, 2008, 28(2):256-65. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/18462266/pubmed\" target=\"_blank\" id=\"18462266\">18462266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Safder S, Demintieva Y, Rewalt M, et al, &quot;Stool Consistency and Stool Frequency are Excellent Clinical Markers for Adequate Colon Preparation After Polyethylene Glycol 3350 Cleansing Protocol: A Prospective Clinical Study in Children,&quot; <i>Gastrointest Endosc</i>, 2008, 68(6):1131-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/18950761 [/pubmed\" target=\"_blank\" id=\"18950761 [\">18950761 [</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):258-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/24345831 /pubmed\" target=\"_blank\" id=\"24345831 \">24345831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Berg MM, van Rossum CH, de Lorijn F, et al, &quot;Functional Constipation in Infants: A Follow-Up Study,&quot; <i>J Pediatr</i>, 2005, 147(5):700-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/16291368/pubmed\" target=\"_blank\" id=\"16291368\">16291368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voskuijl W, de Lorijn F, Verwijs W, et al, &quot;PEG 3350 (Transipeg) Versus Lactulose in the Treatment of Childhood Functional Constipation: A Double Blind, Randomised, Controlled, Multicentre Trial,&quot; <i>Gut</i>, 2004, 53(11):1590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/15479678/pubmed\" target=\"_blank\" id=\"15479678\">15479678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Wexner SD, Beck DE, Baron TH, et al, &quot;A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force From the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),&quot; <i>Surg Endosc</i>, 2006, 20(7):1161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/16799744/pubmed\" target=\"_blank\" id=\"16799744\">16799744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wexner SD, Beck DE, Baron TH, et al, &ldquo;A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force from The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal and Endoscopy (ASGE) and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),&rdquo; <i>Dis Colon Rectum</i>, 2006, 49(6):792-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/16649119/pubmed\" target=\"_blank\" id=\"16649119\">16649119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Youssef NN, Peters JM, Henderson W, et al, &quot;Dose Response of PEG 3350 for the Treatment of Childhood Fecal Impaction,&quot; <i>J Pediatr</i>, 2002, 141(3):410-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-pediatric-drug-information/abstract-text/12219064/pubmed\" target=\"_blank\" id=\"12219064\">12219064</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13070 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2295346\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23536048\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F5599448\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F5599457\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2295374\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F2295348\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5599505\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2295366\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5599449\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2295345\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2295363\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2295357\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2295358\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26888850\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299899\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222409\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2295354\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5599506\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2295368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F2295370\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13070|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-3350-drug-information\" class=\"drug drug_general\">Polyethylene glycol 3350: Drug information</a></li><li><a href=\"topic.htm?path=polyethylene-glycol-3350-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol 3350: Patient drug information \t</a></li></ul></div></div>","javascript":null}